Medistem Inc Information

MediStem has discovered and filed patents on a novel type of stem cell, the Endometrial Regenerative Cell (ERC). This cell appears to have all the major attributes desirable in an ideal cellular therapy: a) Grows well and is scalable for mass production; b) Can be administered intravenously because it selectively homes to damaged tissue; c) Does not require matching with the recipient, allowing for generation of standardized batches that can be shipped to the point of care.. Currently Medistem, together with the Indiana company General Biotechnology, is nearing completion of additional experiments requested by FDA to allow for clinical trial initiation in Q1 2011 as part of its filed IND BB-13898 covering the use of Medistem's "Endometrial Regenerative Cell" (ERC) product in patients at risk of amputation.